Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Blocklisting Interim Review

5 Jun 2006 15:44

Ark Therapeutics Group PLC05 June 2006 Ark Therapeutics Group plc 5 June 2006 SCHEDULE 5 BLOCKLISTING SIX MONTHLY RETURN 1. Name of company Ark Therapeutics Group plc 2. Name of scheme Ark Therapeutics Group Unapproved Share Option Scheme (the "Scheme") 3. Period of return From 3/12/2005 to 2/6/2006 4. Number and class of shares(s) (amount of stock/debt security) not issued under the Scheme 907,401 ordinary shares of 1 pence each 5. Number of shares issued/allotted under the Scheme during period 36,250 6. Balance under the Scheme not yet issued/allotted at end of period 871,151 7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission 126,220,994 ordinary shares admitted to listing on 8/3/2004 Please confirm total number of shares in issue at the end of the period in order for us to update our records: 159,372,573 Contact for queries: Nick Plummer, Ark Therapeutics Group plc, 79 New Cavendish Street, London W1W 6XBTelephone: 0207 388 7722 Person making return:Name: Nick PlummerPosition: Company Secretary Ark Therapeutics Group plc 5 June 2006 SCHEDULE 5 BLOCKLISTING SIX MONTHLY RETURN 1. Name of company Ark Therapeutics Group plc 2. Name of scheme Ark Therapeutics Group Enterprise Management Incentive Share Option Plan (the "Scheme") 3. Period of return From 3/12/2005 to 2/6/2006 4. Number and class of shares(s) amount of stock/debt security) not issued under the Scheme 277,016 ordinary shares of 1 pence each 5. Number of shares issued/allotted under the Scheme during period Nil 6. Balance under the Scheme not yet issued/allotted at end of period 277,016 7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission 126,220,994 ordinary shares admitted to listing on 8/3/2004 Please confirm total number of shares in issue at the end of the period in order for us to update our records: 159,372,573 Contact for queries: Nick Plummer, Ark Therapeutics Group plc, 79 New Cavendish Street, London W1W 6XBTelephone: 0207 388 7722 Person making return:Name: Nick PlummerPosition: Company Secretary This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.